Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Penumbra Inc (PEN)

Penumbra Inc (PEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,008,511
  • Shares Outstanding, K 37,678
  • Annual Sales, $ 747,590 K
  • Annual Income, $ 5,280 K
  • 60-Month Beta 0.73
  • Price/Sales 8.57
  • Price/Cash Flow 147.85
  • Price/Book 6.61
Trade PEN with:

Options Overview Details

View History
  • Implied Volatility 42.26% ( -5.00%)
  • Historical Volatility 63.02%
  • IV Percentile 18%
  • IV Rank 15.72%
  • IV High 76.80% on 05/12/22
  • IV Low 35.82% on 11/17/21
  • Put/Call Vol Ratio 3.33
  • Today's Volume 13
  • Volume Avg (30-Day) 410
  • Put/Call OI Ratio 1.12
  • Today's Open Interest 5,275
  • Open Int (30-Day) 4,528

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.01
  • Number of Estimates 4
  • High Estimate 0.04
  • Low Estimate -0.11
  • Prior Year 0.12
  • Growth Rate Est. (year over year) -108.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.65 +44.28%
on 07/14/22
173.23 -1.18%
on 08/08/22
+36.29 (+26.90%)
since 07/08/22
3-Month
114.86 +49.03%
on 06/16/22
173.23 -1.18%
on 08/08/22
+30.07 (+21.31%)
since 05/10/22
52-Week
114.86 +49.03%
on 06/16/22
293.20 -41.61%
on 09/16/21
-87.21 (-33.75%)
since 08/10/21

Most Recent Stories

More News
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 114.29% and 1.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PEN : 170.49 (+6.91%)
DNAY : 2.3000 (+16.16%)
Penumbra, Inc. Reports Second Quarter 2022 Financial Results

/PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second...

PEN : 170.49 (+6.91%)
Idexx Laboratories (IDXX) Surpasses Q2 Earnings Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 1.30% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IDXX : 398.96 (+2.67%)
PEN : 170.49 (+6.91%)
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 4.17% and 0.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EKSO : 2.0400 (+5.15%)
PEN : 170.49 (+6.91%)
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PEN : 170.49 (+6.91%)
STE : 210.65 (+0.81%)
Penumbra (PEN) Surges 3.6%: Is This an Indication of Further Gains?

Penumbra (PEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

PEN : 170.49 (+6.91%)
SMLR : 43.20 (+2.37%)
Penumbra, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 4, 2022

/PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2022 after...

PEN : 170.49 (+6.91%)
Analysts Offer Insights on Healthcare Companies: Cara Therapeutics (CARA) and Penumbra (PEN)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cara Therapeutics (CARA – Research Report) and Penumbra (PEN – Research Report) with bullish sentiments....

PEN : 170.49 (+6.91%)
CARA : 12.62 (+6.86%)
Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PEN : 170.49 (+6.91%)
OPK : 2.67 (+6.37%)
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PEN : 170.49 (+6.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

3rd Resistance Point 170.74
2nd Resistance Point 168.44
1st Resistance Point 163.95
Last Price 170.49
1st Support Level 157.16
2nd Support Level 154.86
3rd Support Level 150.37

See More

52-Week High 293.20
Fibonacci 61.8% 225.07
Fibonacci 50% 204.03
Fibonacci 38.2% 182.99
Last Price 170.49
52-Week Low 114.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar